OBJECTIVE: The aim of this study is to determine the prevalence and prognosis of unrecognized myocardial infarction (MI) and silent myocardial ischemia in vascular surgery patients. METHODS: In a cohort of 1092 patients undergoing preoperative dobutamine stress echocardiography and noncardiac vascular surgery, unrecognized MI was determined by rest wall motion abnormalities in the absence of a history of MI. Silent myocardial ischemia was determined by stress-induced wall motion abnormalities in the absence of angina pectoris. Beta blockers and statins were noted at baseline. During follow-up (mean: 6+/-4 years), all-cause mortality and major cardiac events (cardiac death or nonfatal MI) were noted. RESULTS: The prevalence of unrecognized MI and silent myocardial ischemia was 23 and 28%, respectively. Both diabetes and heart failure were important predictors of unrecognized MI and silent myocardial ischemia. During follow-up, all-cause mortality occurred in 45% and major cardiac events in 23% of patients. In multivariate analysis, unrecognized MI and silent myocardial ischemia were significantly associated with increased risk of mortality [hazard ratio (HR), 1.86; 95% confidence interval (CI), 1.53-2.25 and HR, 1.74; 95% CI, 1.46-2.06, respectively] and major cardiac events (HR, 2.15; 95% CI, 1.59-2.92 and HR, 1.86; 95% CI, 1.43-2.41, respectively). In patients with unrecognized MI, beta-blockers and statins were significantly associated with improved survival. Statins improved survival in patients with silent myocardial ischemia. CONCLUSIONS: In patients undergoing major vascular surgery, unrecognized MI and silent myocardial ischemia are highly prevalent (23 and 28%) and associated with increased long-term mortality and major cardiac events.
OBJECTIVE: The aim of this study is to determine the prevalence and prognosis of unrecognized myocardial infarction (MI) and silent myocardial ischemia in vascular surgery patients. METHODS: In a cohort of 1092 patients undergoing preoperative dobutamine stress echocardiography and noncardiac vascular surgery, unrecognized MI was determined by rest wall motion abnormalities in the absence of a history of MI. Silent myocardial ischemia was determined by stress-induced wall motion abnormalities in the absence of angina pectoris. Beta blockers and statins were noted at baseline. During follow-up (mean: 6+/-4 years), all-cause mortality and major cardiac events (cardiac death or nonfatal MI) were noted. RESULTS: The prevalence of unrecognized MI and silent myocardial ischemia was 23 and 28%, respectively. Both diabetes and heart failure were important predictors of unrecognized MI and silent myocardial ischemia. During follow-up, all-cause mortality occurred in 45% and major cardiac events in 23% of patients. In multivariate analysis, unrecognized MI and silent myocardial ischemia were significantly associated with increased risk of mortality [hazard ratio (HR), 1.86; 95% confidence interval (CI), 1.53-2.25 and HR, 1.74; 95% CI, 1.46-2.06, respectively] and major cardiac events (HR, 2.15; 95% CI, 1.59-2.92 and HR, 1.86; 95% CI, 1.43-2.41, respectively). In patients with unrecognized MI, beta-blockers and statins were significantly associated with improved survival. Statins improved survival in patients with silent myocardial ischemia. CONCLUSIONS: In patients undergoing major vascular surgery, unrecognized MI and silent myocardial ischemia are highly prevalent (23 and 28%) and associated with increased long-term mortality and major cardiac events.
Authors: R Chiesa; G Melissano; R Castellano; Y Tshomba; E M Marone; E Civilini; D Astore; F Calliari; B Catenaccio; G Coppi; A Carozzo; R Mennella Journal: HSR Proc Intensive Care Cardiovasc Anesth Date: 2009
Authors: Arthur E Stillman; Matthijs Oudkerk; David Bluemke; Jens Bremerich; Fabio P Esteves; Ernest V Garcia; Matthias Gutberlet; W Gregory Hundley; Michael Jerosch-Herold; Dirkjan Kuijpers; Raymond K Kwong; Eike Nagel; Stamatios Lerakis; John Oshinski; Jean-François Paul; Richard Underwood; Bernd J Wintersperger; Michael R Rees Journal: Int J Cardiovasc Imaging Date: 2010-10-24 Impact factor: 2.357
Authors: R Brandon Stacey; Trinity Vera; Timothy M Morgan; Jennifer H Jordan; Matthew C Whitlock; Michael E Hall; Sujethra Vasu; Craig Hamilton; Dalane W Kitzman; W Gregory Hundley Journal: J Cardiovasc Magn Reson Date: 2018-11-22 Impact factor: 5.364
Authors: Hae Young Yang; Min Joo Ahn; Myung Ho Jeong; Youngkeun Ahn; Young Jo Kim; Myeong Chan Cho; Chong Jin Kim Journal: Chonnam Med J Date: 2019-01-25
Authors: Emily B Levitan; Christopher Gamboa; Monika M Safford; Dana V Rizk; Todd M Brown; Elsayed Z Soliman; Paul Muntner Journal: Vasc Health Risk Manag Date: 2013-02-05